RHPN2 and colorectal cancer: RHPN2, which was mutated in 13.64% and 30% of our rNEN-S and rNEN-L subjects, respectively, is required for the proliferation and invasion of multiple cancer cells [34] and can be used as a prognostic biomarker for patients with surgically resected colorectal cancer [50].